Peptides used as cell penetrating peptides

By designing a new WRAP cell penetrating peptide, using short amphiphilic peptide composed of leucine, arginine and tryptophan, the stability and cytotoxicity of existing CPP in siRNA delivery are solved, achieving high efficiency , low toxic cell internalization and targeted delivery effects.

CN112584873BActive Publication Date: 2024-11-12CENT NAT DE LA RECH SCI (C N R S) +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980047720.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-17
Filing Date
2019-07-16
Publication Date
2024-11-12
Estimated Expiration
2039-07-16

Smart Images

  • Figure CN112584873B_ABST
    Figure CN112584873B_ABST
Patent Text Reader

Abstract

The present invention relates to novel peptides comprising the amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, and n=10 to 12, and wherein [X]n comprises 4 Rs, 4 Ls and between 2 and 4 Ws, which can be used as cell penetrating peptides. The present invention also relates to nanoparticles comprising the peptides of the present invention and cargo molecules and their use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to non-naturally occurring peptides that can be used as cell penetrating peptides. More particularly, the peptides of the present invention can self-assemble with cargo molecules such as siRNA to form peptide-based nanoparticles to transfect cargo molecules into cells. The present invention also relates to pharmaceutical compositions comprising the nanoparticles and methods for delivering cargo molecules into cells. Background Art

[0002] RNA interference (RNAi) in mammalian cells has opened up unprecedented research opportunities to exploit this mechanism to treat a variety of diseases. Short interfering RNA (siRNA) is a double-stranded RNA molecule of 20-25 base pairs in length, each containing a 2-nucleotide overhang at the three main ends. The antisense strand of siRNA with sequence complementarity to the target mRNA can induce sequence-specific gene expression inhibition (silencing). SiRNA has been shown to be a potential drug candidate for many difficult-to-treat diseases such as viral infections and cancer.

[0003] The design versatility and highly specific nature of these oligonucleotides highlight their potential as future drugs. However, limitations such as lack of cell permeability and rapid endosomal / lysosomal degradation once inside the cell can be overcome by using specific carriers. Many delivery technologies have been developed based on cationic lipids, polymers, dendrimers and peptides. Among these non-viral carrier materials, cell penetrating peptides (CPPs) are increasingly popular due to their sequence and functional diversity. CPPs are typically short (up to 30 amino acids) peptides derived from a variety of sources (e.g., humans, mice, viruses or pure synthesis). According to their structural characteristics, CPPs can be divided into two categories: arginine-rich CPPs and amphipathic CPPs.

[0004] Amphipathic CPP contains both hydrophilic and hydrophobic domains necessary for cell internalization and interaction with cargo. In primary amphipathic CPP, these domains are distributed according to their positions along the peptide chain, as shown in pVEC (A. Elmquist et al., VE-Cadherin-Derived Cell-Penetrating Peptide, pVEC, with Carrier Functions), Exp. Cell Res. 269 (2001) 237–244), MPG and Pep-1 (S. Deshayes et al., (2005) Cell-penetrating peptides: tools for intracellular delivery of therapeutic agents, Cell. Mol. Life Sci. CMLS. 62, 1839–1849). Secondary amphipathic CPPs are another broad class of peptides in which separation between hydrophilic and hydrophobic domains occurs due to the formation of secondary structures such as alpha helices or beta sheets.Many of the most commonly used CPPs are members of this class, such as penetratin (D. Derossi et al., (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (14) 10444-50), transportan (M. Pooga et al., (1998) Cell penetration by transportan. FASEB J. 12, 67-77), hCT-variant (human calcitonin) (J. Hoyer et al., (2012) Knock-down of a G protein-coupled receptor through efficient peptide-mediated siRNA delivery. J. Control. Release Off. J. Control. Release Soc. 161(3), 826–834), RICK (A. Vaissière et al., (2017) A retro-inversocell-penetrating peptide for siRNA delivery, J Nanobiotechnology. 15(1), 34) or C6M1 (M. Jafari et al., (2014) Serum stability and physicochemical characterization of a novel amphipathic peptide C6M1 for siRNA delivery, PLoS ONE. 9(5): e97797).

[0005] There are two main strategies for vectorizing oligonucleotides using CPPs: directly conjugating oligonucleotides to CPPs (covalent conjugation methods), or forming non-covalent complexes between CPPs and oligonucleotides (nanoparticle-based methods). The formation of non-covalent nanoparticles (NPs) is particularly effective in CPP-mediated delivery of oligonucleotides that have multiple negative charges and are therefore able to form electrostatic complexes with cationic peptides. In addition, the formation of peptide-based nanoparticles is a very easy-to-perform one-step process because no chemical modification is required to allow NP assembly. Therefore, the formation of electrostatic complexes remains the most popular application of CPP-mediated siRNA delivery.

[0006] However, the NPs developed so far suffer from several drawbacks, including lack of stability, poor membrane permeability, low ability to silence target genes in an efficient manner, cytotoxicity, etc.

[0007] Therefore, there remains a need for improved cell penetrating peptides that overcome the above limitations. In particular, there is a need for cell penetrating peptides that can efficiently deliver compounds, such as therapeutic agents, into target cells without producing significant cytotoxic and / or immunogenic effects. Summary of the invention

[0008] Through the work on the developed CPPs and their defects, the inventors have identified three essential amino acids that must be present at specific positions in the sequence to positively affect the solubility, secondary structure, low cytotoxicity and high uptake efficiency of the peptides. More particularly, the inventors have developed new CPPs consisting only of leucine (L), arginine (R) and tryptophan (W) residues, which at least partially overcome the shortcomings of previous CPPs. The tryptophan residues of these new short amphipathic peptides (also referred to as WRAPs for amphipathic peptides rich in W and R) can be scattered throughout the sequence or clustered in one domain of the sequence. In general, the peptides of the present invention show higher overall transfection efficacy and lower degree of cytotoxicity.

[0009] Therefore, one object of the present invention is to provide a non-naturally occurring peptide comprising the amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, n=10 to 12, and wherein [X]n comprises 4 Rs, 4 Ls and 2 to 4 Ws.

[0010] In a specific embodiment, the peptide comprises the amino acid sequence LL-[X]m-RLL, wherein m=9 to 11.

[0011] In a specific embodiment, [X]n or [X]m comprises between 2 and 4 Ws clustered or interspersed in the amino acid sequence.

[0012] Alternatively, or in addition, [X]n or [X]m may comprise at least one cluster consisting of LLs, preferably two clusters consisting of LLs.

[0013] In a specific embodiment, the peptide comprises or consists of an amino acid sequence selected from the group consisting of

[0014] -LLWRLWRLLWRLWRLLSEQ ID N°1-CPP1),

[0015] -LLRLLRWWWRLLRLL(SEQ ID N°2–CPP2),

[0016] -LLRLLRWWRLLRLL(SEQ ID N°3–CPP3), and

[0017] -LLRLLRWWWWRLLRLL(SEQ ID N°4–CPP4)

[0018] The peptides of the invention are particularly useful as cell penetrating peptides (CPPs). They are suitable for penetrating the plasma membrane of mammalian cells and for use as transfection agents.

[0019] A further object of the present invention is to provide nanoparticles comprising the peptide of the present invention and a cargo molecule. The cargo molecule may be selected from nucleic acids, peptides, proteins, lipids, small molecules, pharmaceutically active agents, and any mixture thereof. Advantageously, the cargo molecule is a nucleic acid selected from DNA molecules, RNA molecules, PNA molecules, siRNA molecules, PMO molecules, antisense molecules, LNA molecules, mcDNA molecules, miRNA molecules, CRISPR / Cas9 molecules, plasmids, ribozymes, aptamers, spiegelmers, and decoy molecules.

[0020] The nanoparticles of the present invention can be used to prepare pharmaceutical compositions. The present invention also provides a pharmaceutical composition comprising such nanoparticles and a pharmaceutically acceptable carrier.

[0021] Another object of the present invention is to provide a method for delivering cargo molecules into cells in vitro and / or into tissues and / or organs ex vivo, the method comprising the step of contacting the cells with the nanoparticles of the present invention comprising the cargo molecules.

[0022] The nanoparticles of the present invention may also be used in a method for delivering a cargo molecule to an animal, the method comprising the step of administering to the animal the nanoparticles of the present invention comprising the cargo molecule. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1: 3D structure of the amphipathic peptide used predicted by PEPstrMOD under hydrophilic conditions. Surface and ribbon structure diagram of the peptide. For the surface diagram, two views are given to determine its amphipathic properties: along the N-terminal to C-terminal axis and after a 90° rotation. Tryptophan residues are shown in red, arginine in blue, and the rest in yellow.

[0024] Figure 2 : Evaluation of the ability of the amphiphilic peptides to form complexes in the presence of siRNA. (A) Preformed CPP:siRNA complexes were analyzed by electrophoresis on GelRed-stained agarose gels (1% wt / vol). Data are presented as: mean ± SD, n = 3. (B) Transmission electron microscopy (TEM) images of nanoparticles based on CPP1 and CPP2. Images of CPP:siRNA nanoparticles in ultrapure water (R = 20, 40 μM CPP). The scale bars of the magnified images correspond to 500 nm and 100 nm.

[0025] Figure 3 : Evaluation of the ability of the amphiphilic peptides to form complexes in the presence of plasmids. A) Graphical representation of the migration of plasmid pGL3 in agarose gels. Preformed CPP:pGL3 complexes were formulated at different loading ratios (CR) and analyzed by electrophoresis on GelRed-stained agarose gels (0.5% wt / vol). Data are expressed as: mean ± SD, n = 2. Dose-dependent expression of luciferase in MEF cells (B) or MCF-7 cells (C) after CPP2:pGL3 transfection. Based on the gel migration properties of CPP2:pGL3, nanoparticles were formulated at three different plasmid concentrations (62.5 ng, 125 ng and 250 ng) at CR1. NT = untreated cells. Data are expressed as: mean ± SD, n = 2.

[0026] Figure 4 : Cellular evaluation of knockdown efficiency of CPP:siRNA nanoparticles. (A) Relative Luc activity (%FLuc / NLuc) and relative toxicity (LDH quantification) after transfection with CPP:siFLuc complexes at different molar ratios R at a constant siFLuc concentration of 20 nM in U87 cells. (B) On U87 cells, relative Luc activity (%FLuc / NLuc) depends on the total transfection time (24 h vs. 36 h). (C) Relative Luc activity (%FLuc / NLuc) and relative toxicity (LDH quantification) after transfection of U87 cells with CPP:siFLuc nanoparticles at different siFLuc concentrations (constant molar ratio R=20). RNAiMAX was used to transfect siFLuc at 20 nM as described by the supplier (RNAi lane in "control" plate). Abbreviations: R = molar ratio, siFLuc = siRNA FLuc, siSCR = scrambled siRNA, NT = untreated cells, Ctrl = control, nd = not determined.

[0027] Figure 5 : Graphical representation of the reduction of firefly luciferase expression on U87 cells, in isoform L (CPP2[L]) or in isoform (CPP2[D]), depending on the concentration of siRNA vectored by CPP2. FLuc / NLuc values ​​are normalized to the condition of untreated cells (NT).

[0028] Figure 6 : Graphical representation of firefly luciferase silencing depending on the concentration of siRNA vectored by CPP1 or CPP2. At all siRNA concentrations, this mode of delivery was effective even in the presence of 10% serum (U87 cells). FLuc / NLuc values ​​were normalized to the condition of untreated cells (NT).

[0029] Figure 7 : Graphical representation of firefly luciferase expression reduction (U87 cells) performed in different laboratories and using different readout methods. FLuc / NLuc values ​​are normalized to the condition of untreated cells (NT).

[0030] Figure 8: Comparison of CPP:siRNA with C6M1:siRNA or other derivative CPPs. (A) Graphical representation of the knockdown efficiency of firefly luciferase expression after CPP:siFluc transfection in U87 cells compared to C6M1:siFLuc. Incubation conditions: 5,000 cells / well, nanoparticles with 200 nM peptide and 10 nM siRNA (vol:vol formulation), incubation time 1 hour 30 minutes. FLuc / NLuc values ​​are normalized to the conditions of untreated cells (NT). n=2 independent experiments, triplicate. (B) Graphical representation of the knockdown efficiency of firefly luciferase expression after CPP:siFluc transfection in U87 cells (vol:vol formulation) compared to derivative CPP nanoparticles with mutations in the leucine "doublets" (see Table 1). Incubation conditions: 5,000 cells / well, CPP:siRNA ratio = 20:1 at the indicated siRNA concentrations, incubation time 1 hour 30 minutes. FLuc / NLuc values ​​are normalized to the conditions of untreated cells (NT). n = 2 independent experiments, triplicate. (C) Graphical representation of the knockdown efficiency of firefly luciferase expression after CPP:siFluc transfection (dilution preparation) loaded with siFluc in U87 cells compared to derivative CPP2 nanoparticles with mutations (see Table 1). Incubation conditions: 5,000 cells / well, CPP:siRNA ratio = 20:1 at the indicated siRNA concentrations, incubation time 1 hour 30 minutes. FLuc / NLuc values ​​are normalized to the conditions of untreated cells (NT). n = 3 independent experiments, triplicate.

[0031] Fig. 9: Evaluation of CPP1:siRNA and CPP2:siRNA PBN activity. (A) Relative FLuc activity (%) after CPP:siFLuc PBN transfection in different cell lines at the indicated siRNA-FLuc concentrations. U87: human glioblastoma cell line, KB: Hela-derived keratinocyte cell line, HuH7: human hepatoma cell line, RM1: murine prostate cancer cell line, Neuro2a: murine neuroblastoma cell line, MCF7: human breast cancer cell line, MDA-MB-231: human breast adenocarcinoma, MEF-RAS: Ras-modified mouse embryonic fibroblasts, A549: human adenocarcinoma alveolar basal epithelial cells, HT29: human colon cancer cell line, CMT93: rectal cancer cell line, GL261: murine glioblastoma cell line. (B) CDK4 silencing after CPP:siRNA nanoparticle transfection in U87 cells at the indicated siRNA-CDK4 concentrations. Abbreviations: siSCR = scrambled siRNA, NT = untreated cells. (C) Activity of CPP1:siCDK4 nanoparticles and siRNA transfection agents against endogenous CDK4 protein expression in U87 cells. Comparison of RNAiMAX activity. Black dashed line = no toxicity, red dashed line = dose-dependent toxicity. (D) For evaluating the activity of CPP2 nanoparticles and Clonogenic assay of cytotoxicity compared to RNAiMAX. Different CPP2:siRNA nanoparticles (ratio 20, siRNA concentration 50 nM) were incubated on MEF-Ras cells (14 days) and compared to CPP2 peptide alone (100 nM) or to RNAi:siRNA (siRNA concentration 20 nM) conditions. (E) CDK4 silencing after CPP:siRNA nanoparticle transfection in U87 cells after three days of culture, following a single dose of siCDK4 (20 nM), a double dose of siCDK4 (20 nM + 20 nM), or a triple dose of siCDK4 (20 nM + 20 nM + 20 nM). Abbreviations: siSCR = scrambled siRNA, NT = untreated cells.

[0032] Fig.10: Internalization kinetics of CPPP:siRNA nanoparticles. (A) Relative FLuc activity (%) after CPP:siFLuc nanoparticle transfection in U87 cells at 20 nM siRNA-FLuc concentration and different incubation times in minutes. (B) CDK4 silencing after CPP:siRNA nanoparticle transfection in U87 cells at 20 nM siRNA-CDK4 concentration and different incubation times in minutes. (C) Visualization of cellular distribution of Cy5-labeled siRNA (siRNA-Cy5=20 nM, R=20) vectored by CPP1 or CPP2 nanoparticles in living U87 cell lines. Cell nuclei were labeled with Hoechst 33342 dye. White bars represent 20 μm. (D) Comparison of the internalization kinetics of CPP1:siRNA-Cy3b and CPP2:siRNA-Cy3b by spinning disk (siRNA-Cy3b = 20 nM, R = 20) with images recorded every 5 seconds for 1200 seconds. Afterwards, the percentage of the mean gray value is plotted against time (mean ± SD; 2-5 independently counted cells from 2 to 3 independent experiments).

[0033] Fig.11 : Nanoparticles induce a reduction in firefly luciferase expression in vivo on a tumor model in xenograft mice. (A) Representative images of dual bioluminescence (Fluc and Nluc) and tumor fluorescence (U87-CMV-Fluc-CMV-iRFP-IRES) at the indicated times after CPP2 nanoparticle:siFluc injection. (B) Quantification of Fluc and Nluc luciferase immediately after intratumoral injection of CPP2 nanoparticle:siFluc (15 μg of siRNA). Statistical analysis (mean ± SEM, n = 11): One-way ANOVA with Dunnet post hoc test compared to 0 h (= control), *p < 0.05. (C) Quantification of Fluc mRNA immediately after intratumoral injection of CPP2 nanoparticle:siFluc (20 μg of siRNA). Statistical analysis (mean ± SD, n = 4): t-test compared to 0 h (= control), ***p = 0.0009. The level of Fluc mRNA was expressed as a ratio to the mRNA of GAPDH protein (Fluc / GAPDH).

[0034] Fig.12: siRNA mixtures were vectored by CPP nanoparticles. (A) Simultaneous transfection of 2 siRNAs by PBN: [CPP2: siCDK4 / siCycB1] mixture showed a dose-dependent reduction in endogenous CDK4 and Cyclin B1 protein expression in U87 cells. (B) Transfection of 2 siRNAs by PBN at different stoichiometric ratios: [CPP1: siCDK4 / siCycB1] mixture showed a reduction in endogenous CDK4 and Cyclin B1 (U87 cells) protein expression inversely proportional to the amount of each siRNA.

[0035] Fig.13 : Development of multi-grafted nanoparticles. (A) Relative FLuc activity (%) after transfection of siFluc with RGD-Ahx-CPP2 peptide (R-CPP2, R=20) in a dose-dependent manner. (B) CPP2:RGD-Ahx-CPP mixture (CPP2:R-CPP2 ratio from 100%:0% to 0%:100%) did not affect the silencing of Fluc luciferase activity (R=20, 20nM siFluc). (C) Effect of PEGylation rate of CPP1 nanoparticles on Fluc luciferase activity (R=20, 20nM siFluc). (D) Effect of multi-grafted CPP2 nanoparticles on Fluc luciferase activity (R=20, 20nM siFluc). (E) Schematic diagram of peptide nanoparticles made from simple mixtures of different entities.

[0036] Fig.14 : Graphical representation of firefly luciferase silencing in U87 cells, depending on the formulation conditions applied. U87 cells were seeded in P96 well plates (5,000 cells / well). Nanoparticles were formulated using "vol:vol" conditions (final concentrations CPP:siRNA 100nM:5nM; 200nM:10nM and 400nM:20nM) or at high concentrations (CPP [10μM]:siRNA [0.5μM]) followed by dilution (= "diluted" conditions). The incubation time of the nanoparticles was 1 hour and 30 minutes in serum-free medium. After the addition of serum, the cells were incubated for 36 hours and then the luciferase assay was performed. FLuc / NLuc values ​​were normalized to the conditions of untreated cells (NT). n=2 independent experiments in triplicate.

[0037] Fig.15: Evaluation of the activity of CPP1:siRNA and CPP2:siRNA PBN on cell suspensions. (A) Relative FLuc activity (%) after transfection of CPP:siFLuc nanoparticles in a dose-dependent manner (siRNA = 10 nM, 20 nM and 50 nM) in U87 cell suspensions. Incubation conditions: 10,000 cells / well, CPP:siRNA ratio = 20:1 at the indicated siRNA concentrations, incubation time of 1.5 h in serum-free medium. FLuc / NLuc values ​​are normalized to the condition of untreated cells (NT). Abbreviations: siSCR = scrambled siRNA, siFLuc = firefly luciferase-specific siRNA. n = 2 independent experiments, triplicate. (B) Relative FLuc activity (%) after transfection of CPP:siFLuc nanoparticles in a dose-dependent manner (siRNA = 10 nM, 20 nM and 50 nM) in U87 cell suspensions. Incubation conditions: 10,000 cells / well, CPP:siRNA ratio = 20:1 at the indicated siRNA concentrations, incubation time of 1.5 hours in medium containing 10% serum. FLuc / NLuc values ​​are normalized to the condition of untreated cells (NT). Abbreviations: siSCR = scrambled siRNA, siFLuc = firefly luciferase-specific siRNA. n = 2 independent experiments, triplicate. (C) Relative FLuc activity (%) after transfection of CPP:siFLuc nanoparticles in a suspension of U937 human macrophages stably transfected with firefly luciferase in a dose-dependent manner (siRNA = 10 nM, 20 nM and 50 nM). Incubation conditions: 10,000 cells / well, CPP:siRNA ratio = 20:1 at the indicated siRNA concentrations (or siRNA alone), incubation time of 1.5 hours in medium without serum. FLuc values ​​were normalized to the condition of untreated cells (NT). n = 2 independent experiments in triplicate.

[0038] Fig.16 : Evaluation of MBBO and plasmid co-transfection in the context of cystic fibrosis. (A) Preformed CPP1:MBBO complexes were analyzed by electrophoresis on GelRed-stained agarose gels (1% wt / vol). Data are presented as mean ± SD, n = 2. (B) The average size of CPP1:MBBO complexes was measured by dynamic light scattering (DLS) (R = 5, 10 μM CPP1). (C) Lipofectamine was used to co-transfect the CPP1:MBBO complexes. TM RNAiMAX, Bronchial Beas-2b cells were transfected with 1 μg of CFTR encoding plasmid (PJ) or CPP2 and 100 nM MBBO using RNAiMAX or CPP1. The amount of CFTR transcripts and the housekeeping gene GAPDH was determined by qPCR. CFTR values ​​were first normalized to GAPDH and then to control conditions using MBBO without 3'-UTR binding properties (MBBO-Ctrl=1). DETAILED DESCRIPTION

[0039] definition

[0040] As used herein, the term "peptide" or "peptide molecule" refers to any naturally occurring or non-naturally occurring (eg, produced by chemical synthesis or recombinant DNA technology) linear macromolecule comprising a plurality of natural or modified amino acid residues linked by peptide bonds.

[0041] As used herein, the term "amino acid residue" refers to any of the 20 "standard" amino acids naturally incorporated into peptides. The amino acids are represented herein by their single-letter or three-letter codes according to the following nomenclature: A: alanine (Ala); C: cysteine ​​(Cys); D: aspartic acid (Asp); E: glutamic acid (Glu); F: phenylalanine (Phe); G: glycine (Gly); H: histidine (His); I: isoleucine (Ile); K: lysine (Lys); L: leucine (Leu); M: methionine (Met); N: asparagine (Asn); P: proline (Pro); Q: glutamine (Gln); R: arginine (Arg); S: serine (Ser); T: threonine (Thr); V: valine (Val); W: tryptophan (Trp), and Y: tyrosine (Tyr). Typically, the amino acid residues of the peptides of the present invention exist as L-isomers or D-isomers. As used herein, the term "non-natural amino acid residue" means a non-encoded or non-proteinogenic amino acid, which is not naturally encoded or found in the genetic code of any organism. The term "modified amino acid residue" used herein means a non-standard amino acid, such as an amino acid modified post-translationally. Examples of post-translational modifications include phosphorylation, glycosylation, acylation (e.g., acetylation, myristoylation, palmitoylation), alkylation, carboxylation, hydroxylation, saccharification, biotinylation, ubiquitination, chemical property changes (e.g., β-elimination deimidation, deamidation), and structural changes (e.g., formation of disulfide bonds).

[0042] Cell Penetrating Peptides

[0043] The present invention relates to non-naturally occurring peptides comprising the amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, n=10 to 12, and wherein [X]n comprises 4 Rs, 4 Ls and 2 to 4 Ws, preferably 3 to 4 Ws.

[0044] The present inventors have surprisingly found that such peptides, referred to herein as peptides of the invention, are suitable for acting as cell penetrating peptides (CPPs) and can thereby deliver cargo molecules to the cytoplasm of cells, preferably across the plasma membrane of mammalian cells.

[0045] The peptides of the invention have a length of 14 to 16 amino acid residues, all of which are selected from R, L and W. In fact, the inventors have found that the specific distribution of these three amino acid residues in the amino acid sequence of the peptides leads to peptides that are particularly interesting as CPPs. In fact, the peptides show a high cellular uptake capacity after being internalized, and the cytotoxic and / or immunogenic effects on their corresponding target cells are not significant (i.e., at least at concentrations sufficient to mediate cell transfection and / or penetration, they do not interfere with cell viability). The term "not significant" as used herein is understood to mean that less than 30%, in particular less than 20% or 10%, of the target cells killed after the internalization of the peptides of the invention. The skilled person is well aware of methods for determining the cytotoxicity of a given compound and / or the viability of a given target cell to which such a compound is applied (see also, for example, Ausubel, FM et al. (2001) Current Protocols in Molecular Biology, Wiley & Sons, Hoboken, NJ, USA).

[0046] As used herein, the term "cellular uptake ability" refers to the ability of the peptide to pass through cell membranes (i.e., plasma membranes, endosomal membranes, and endoplasmic reticulum membranes) and / or to direct a given cargo molecule through these cell membranes (i.e., its transfection ability). Peptides with the ability to pass through cell membranes are referred to herein as "cell penetrating peptides" or "CPPs". Many methods for determining the internalization behavior and / or transfection ability of a given peptide have been established in the art, for example, by connecting a detectable marker (e.g., a fluorescent dye) to the peptide (and / or to a cargo molecule to be transfected) or by fusing the peptide to a reporter molecule, so that once cellular uptake of the peptide occurs, it can be detected, for example, by means of FACS analysis or by specific antibodies (see, e.g., Ausubel, FM et al. (2001) Current Protocols in Molecular Biology, Wiley & Sons, Hoboken, NJ, USA). The technician also knows how to select the corresponding concentration range of the peptide and the applicable cargo to be used in such a method, which may depend on the nature of the peptide, the size of the cargo, the cell type used, etc.

[0047] In a specific embodiment, the peptide of the invention comprises the amino acid sequence LL-[X]m-RLL, wherein m=9-11.

[0048] Advantageously, [X]n or [X]m comprises a cluster consisting of WW, WWW or WWWW. Preferably, such a cluster is central, that is to say there is the same number of amino acid residues on each side of the tryptophan cluster.

[0049] In a specific embodiment, [X]n or [X]m comprises at least one cluster consisting of LLs, preferably two clusters consisting of LLs.

[0050] Advantageously, the peptides of the invention have a net positive charge of five.

[0051] In a specific embodiment, the peptide comprises or consists of an amino acid sequence selected from the group consisting of

[0052] -LLWRLWRLLWRLWRLL(SEQ ID N°1),

[0053] -LLRLLRWWWRLLRLL(SEQ ID N°2),

[0054] -LLRLLRWWRLLRLL(SEQ ID N°3), and

[0055] -LLRLLRWWWWRLLRLL(SEQ ID N°4).

[0056] In a specific embodiment, the peptide further comprises one or more entities selected from L-amino acids, D-amino acids, non-natural amino acids, modified amino acids, cysteamide, thiol, amide, carboxyl, optionally substituted linear or branched C1-C6 alkyl, primary or secondary amine, osidic derivatives, lipids, phospholipids, fatty acids, cholesterol, polyethylene glycol, nuclear localization signals and / or targeting molecules covalently linked to the C-terminus of the amino acid sequence, and / or wherein the peptide further comprises one or more chemical entities selected from L-amino acids, D-amino acids, non-natural amino acids, modified amino acids, amines, acetyl, optionally substituted linear or branched C1-C6 alkyl, primary or secondary amine, osidic derivatives, lipids, phospholipids, fatty acids, cholesterol, polyethylene glycol, nuclear localization signals and / or targeting molecules covalently linked to the N-terminus of the amino acid sequence.

[0057] Nanoparticles

[0058] The present invention also provides nanoparticles comprising at least one peptide of the present invention, the peptide being complexed with at least one cargo molecule. Such a cargo molecule may be any cargo molecule as defined herein. According to a specific embodiment, the nanoparticle may comprise more than one peptide of the present invention. In particular, the nanoparticle may comprise a plurality of identical or different peptides. The nanoparticle may also comprise more than one cargo molecule. In particular, the nanoparticle may comprise a plurality of identical or different cargo molecules.

[0059] Advantageously, the size of the nanoparticles is between 50 and 300 nm, preferably between 100 and 200 nm.

[0060] In one embodiment, the complex between the peptide and the cargo molecule can be formed based on non-covalent bonds. Such non-covalent bonds can be ionic bonds, hydrogen bonds or hydrophobic interactions or a combination of such bonds.

[0061] Alternatively, the complex between the peptide and the cargo molecule is formed by a covalent bond. Such a covalent bond is preferably formed between a suitable reactive group of the peptide and the cargo, more preferably between the end of the peptide of the present invention and the cargo molecule. Depending on the chemical nature or cargo molecule, the part, group or residue that forms such a covalent bond may vary, and creating such a bond is within the skill of those skilled in the art.

[0062] Advantageously, the cargo molecule is selected from the group consisting of nucleic acids, peptides, proteins, lipids, small molecules, pharmaceutically active agents, and any mixtures thereof.

[0063] The peptides of the invention are particularly suitable for complexing with nucleic acid molecules. Therefore, a specific object of the present invention is to provide nanoparticles comprising the peptides of the invention and nucleic acid molecules or any mixture thereof, wherein the nucleic acid molecules are selected from the group consisting of DNA molecules, RNA molecules, PNA molecules, siRNA molecules, PMO molecules, antisense molecules, LNA molecules, mcDNA molecules, miRNA molecules, CRISPR / Cas9 molecules, plasmids, ribozymes, aptamers, spiegelmers and decoy molecules.

[0064] As used herein, the term "miRNA molecule" (or "miRNA") refers to an endogenous RNA molecule derived from a genomic locus that is processed from a transcript that forms a local RNA precursor miRNA structure. The length of a mature miRNA is typically 20, 21, 22, 23, 24, or 25 nucleotides, but other nucleotide numbers, such as 18, 19, 26, or 27 nucleotides, may also be present.

[0065] As used herein, the term "shRNA molecule" (i.e., short hairpin RNA molecule) refers to an artificial single-stranded interfering RNA molecule that contains both the sense and antisense strands of an "siRNA duplex" in a stem-loop or hairpin structure. The length of the stem of the hairpin structure is typically in the range of 19 to 29 nucleotides, and the length of the loop is typically in the range of 4 to 15 nucleotides.

[0066] The term "siRNA molecule" refers to a small interfering RNA directed against a target nucleic acid, preferably an mRNA, encoding a target molecule. siRNA is a double-stranded RNA that is generally about 21 to 23 nucleotides in length. The sequence of one of the two RNA strands corresponds to the sequence of the target nucleic acid to be degraded. Therefore, knowing the nucleic acid sequence of the target molecule, preferably the mRNA sequence, a double-stranded RNA can be designed in which one of the two strands is complementary to the mRNA of the target molecule, and after the siRNA is applied to a system containing the gene, the corresponding corresponding target nucleic acid will be degraded, thereby reducing the level of the corresponding protein.

[0067] The term "ribozyme" refers to a catalytically active nucleic acid, which preferably consists of RNA consisting essentially of two parts. The first part exhibits catalytic activity, while the second part is responsible for the specific interaction with the target nucleic acid.

[0068] The term "aptamer" refers to a D-nucleic acid that is single-stranded or double-stranded and specifically interacts with a target molecule. Aptamers are currently used as therapeutic agents.

[0069] The term "spiegelmer" refers to L-nucleic acids, ie composed of L-nucleotides. Spiegelmers are characterized by the fact that they have a very high stability in biological systems and, comparable to aptamers, interact specifically with the target molecules against which they are directed.

[0070] In another embodiment, the cargo molecule is a peptide consisting of at least two amino acids covalently linked, preferably covalently linked by a peptide bond. In one embodiment, the peptide consists of L-amino acids, D-amino acids, unnatural amino acids or mixtures thereof. Alternatively, the cargo molecule is a protein.

[0071] In another embodiment, the cargo molecule is a small molecule, preferably with a molecular weight of 1,000 Da or less. In particular, the small molecule is a drug or a drug candidate.

[0072] In another embodiment, the cargo molecule is a pharmaceutically active agent.

[0073] In another embodiment, the cargo molecule is a lipid.

[0074] In another embodiment, the cargo molecule is an antibody or a protein.

[0075] Pharmaceutical composition

[0076] A further object of the present invention is to provide a pharmaceutical composition comprising the nanoparticles of the present invention (at least one peptide linked to at least one cargo molecule) and one or more pharmaceutically acceptable carriers. In fact, the nanoparticles of the present invention can be advantageously used in the manufacture of pharmaceutical compositions.

[0077] The term "pharmaceutical composition" as used herein relates to a composition for administration to a subject, preferably a human patient. Pharmaceutical compositions according to the present invention include any pharmaceutical dosage form established in the art, such as capsules, microcapsules, cachets, pills, tablets, powders, granules, multiparticulate preparations (e.g., beads, granules or crystals), aerosols, sprays, foams, solutions, dispersions, tinctures, syrups, elixirs, suspensions, water-in-oil emulsions such as ointments, and oil-in-water emulsions such as creams, lotions, balms, skin patches, drops, pastes and suppositories.

[0078] Pharmaceutical compositions of the invention include formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), peritoneal and parenteral (including intramuscular, subcutaneous and intravenous) administration, or administration by inhalation or insufflation. Administration may be local or systemic.

[0079] Another aspect of the invention is the use of a nanoparticle as described above as a medicament and as a marker or imaging agent.

[0080] The present invention also relates to a method for delivering a molecule into a cell in vitro, the method comprising the step of contacting the cell with a nanoparticle or a pharmaceutical composition as described above. The present invention also relates to a method for delivering a molecule into a tissue and / or an organ ex vivo, the method comprising the step of contacting the tissue and / or an organ with a nanoparticle or a pharmaceutical composition as described above.

[0081] The present invention also relates to a method for delivering a cargo molecule in vivo, said method comprising an administration step of contacting said animal with a nanoparticle according to any one of claims 13 to 17, said nanoparticle comprising said cargo molecule.

[0082] Several aspects of the invention are further developed in the following examples, which are illustrated by the figures (described in the examples).

[0083] Example

[0084] Materials & Methods

[0085] Material .Dioleylphosphatidylglycerol (DOPG) and dioleylphosphatidylcholine (DOPC) phospholipids, cholesterol (Chol), sphingomyelin (SM) were purchased from Avanti Polar Lipids. Large unilamellar vesicles (LUVs) were prepared from a lipid mixture of DOPC / SM / Chol (2:2:1) by an extrusion method as previously reported (A. Vaissière et al., (2017) A retro-inverso cell-penetrating peptide for siRNA delivery, J Nanobiotechnology. 15(1), 34).

[0086] Different siRNA sequences (unlabeled and Cy5-labeled) were purchased from Eurogentec. Cy3b-labeled siRNA was purchased from BioSynthesis. The following siRNAs were used: anti-firefly luciferase (siFLuc): 5'-CUU-ACG-CUG-AGU-ACU-UCG-AdTdT-3' (SEQ ID N°5) (sense chain) and the corresponding scrambled version of anti-luciferase (siSCR): 5'-CAU-CAU-CCC-UGC-CUC-UAC-UdTdT-3' (SEQ ID N°6) (sense chain) and anti-cyclin-dependent kinase 4 (siCDK4) siRNA based on the following: 5'-CAG-AUC-UCG-GUG-AAC-GAU-GdTdT-3' (SEQ ID N°7) (antisense chain) and scrambled version: 5'-AAC-CAC-UCA-ACU-UUU-UCC-CAA-dTdT-3' (SEQ ID N°8) (antisense chain).

[0087] The siRNA stock solution was prepared in RNase-free water, peptide stock solutions and CPP:siRNA complexes were prepared as previously published (Konate K et al. (2016) Optimisation of vectorisation property: a comparative study for a secondary amphipathic peptide. Int J Pharm. 509, 71-84).

[0088] Peptide synthesis and modification: Peptides were purchased from LifeTein or produced in our laboratory using standard Fmoc chemistry (sequences in Table 1) and purified by HPLC / MS (>95% purity). PEG entities were grafted onto purified CPPs with a cysteine ​​residue at the N-terminus using a 4 molar excess of PEG maleimide 2,000 (Nanocs) during 23 hours at room temperature. During the synthesis, the RGD targeting sequence was grafted onto the CPP with aminocaproic acid as a linker at the N-terminus.

[0089] Peptide structure prediction: The tertiary structure of WRAP was predicted using the PEPstrMOD server (http: / / osddlinux.osdd.net / raghava / pepstrmod / ) (H. Kaur et al., (2007) Protein Pept. Lett. 14, 626-630; S. Singh et al., (2015) Biol. Direct. 10, 73).

[0090] Circular Dichroism (CD) Measurement CD spectra of peptides in solution or in the presence of liposome vesicles were recorded on a Jasco 810 (Japan) dichroism meter in a quartz suprasil cuvette (Hellma) with a pathlength of 1 mm. The same peptide concentration (40 μM) was used for each condition. Spectra were obtained from 3 accumulations between 190 nm and 260 nm using a data spacing of 0.5 nm, a bandwidth of 1 nm and standard sensitivity.

[0091] Agarose gel shift assay CPP:siRNA complexes were formed at different ratios in 5% glucose and pre-incubated for 30 minutes at room temperature. Each sample was analyzed by agarose gel electrophoresis (1% w / v) stained with GelRed (Interchim) for UV detection as described previously.

[0092] Dynamic light scattering (DLS) and zeta potential (ZP).CPP:siRNA nanoparticles were evaluated based on particle distribution average size (Z-average) and uniformity (PdI) using a Zetasizer NanoZS (Malvern). Zeta potential was measured in 5% glucose + 5 mM NaCl. All results were obtained from three independent measurements (each measurement was run three times at 25°C).

[0093] Transmission electron microscopy (TEM). For transmission electron microscopy (TEM), a 5 μl drop of the suspension was deposited on a 300 mesh grid coated with carbon for 1 minute, blotted dry by touching filter paper, and then placed on a drop of 2% uranyl acetate solution. After 1 minute, excess stain was removed by touching the edge with filter paper, the grid was dried at room temperature for several minutes, and examined using a Jeol 1200EX2 transmission electron microscope operating at 100 kV accelerating voltage. Data were collected with a SIS Olympus Quemesa CCD camera.

[0094] Culture conditions. Human glioblastoma U87 MG cells stably transfected with plasmids encoding firefly luciferase and Nanoluc luciferase (FLuc-NLuc) (Aldrian G et al., J. Control. Release 2017) were grown in complete medium: DMEM with GlutaMAX TM (Life Technologies), penicillin / streptomycin (Life Technologies), 10% heat-inactivated fetal bovine serum (FBS, PAA), non-essential amino acids NEAA 1X (Life Technologies). In addition, hygromycin B (Invitrogen, 50 μg / ml) was added as a selection antibiotic.

[0095] Hela-derived keratinocyte cell line (KB), murine neuroblastoma cell line (Neuro2a), human hepatoma cell line (HuH7), human breast cancer cell line (MCF7) and adenocarcinoma human alveolar basal epithelial cell line (A549) were grown in the same complete medium without the addition of selective antibiotics.

[0096] The mouse prostate cancer cell line (RM1) was grown in the same complete medium supplemented with blasticidin S (Invitrogen, 10 μg / mL), while the human colon cancer cell line (HT29), rectal cancer cell line (CMT93), and murine glioblastoma cell line (GL261) were grown in the same complete medium supplemented with hygromycin B (Invitrogen, 1,400 μg / mL, 500 μg / mL, and 150 μg / mL, respectively) as the selection antibiotic.

[0097] Human breast adenocarcinoma (MDA-MB-231) was grown in the same complete medium supplemented with G418 (Invitrogen, 100 μg / mL) as the selection antibiotic.

[0098] The immortalized human bronchial epithelial cell line BEAS-2B obtained from ATCC was grown in Dulbecco's modified Eagle's medium (DMEM, Fisher Scientific) supplemented with 5% fetal bovine serum (FBS) (Eurobio), 1% Ultroser G (Pall BioSepra), 1% antibiotic-antimycotic (Life Technologies SAS) and 1% L-glutamine (Life Technologies SAS), and T-type large immortalized mouse embryonic fibroblasts (MEFs) were grown in DMEM / F12 medium (Life Technologies) supplemented with penicillin / streptomycin (Life Technologies) and 10% heat-inactivated fetal bovine serum (FBS, PAA).

[0099] All cells were maintained in a humidified incubator at 37°C with 5% CO2.

[0100] Cell culture and transient transfection: 200,000 Beas-2b cells were seeded in 6-well plates as described previously (Viart V et al., Eur Respir J. 2015). Cells were transfected with 1 μg pm-cDNA-CFTR-3′UTR or CPP2 and with 100 nM MBBO using RNAiMAX or CPP1.

[0101] RNA extraction and RT-qPCR: Total RNA was extracted, reverse transcribed and amplified as previously described (Viart V et al., Eur J Hum Genet 2012). Reverse transcription was performed using 1 μg of total RNA and MMLV reverse transcriptase, and qPCR was performed using a 1:10 dilution of the first-strand DNA. Relative expression levels were calculated using the comparative DDCt method using GAPDH mRNA as an endogenous control.

[0102] Clonogenic assay. MEF cells were seeded in 6-well plates (250 cells / well). 24 hours after seeding, cells were incubated with nanoparticles (R=20, 50 nM siRNA) for 14 days. For colony visualization, cells were fixed with methanol:acetic acid (3:1) solution at 4°C for 20 minutes and labeled with Giemsa (Sigma Aldrich) / H2O (3.5:10) solution at room temperature for 20 minutes. The remaining staining solution was removed with water and the plates were dried for several hours. Each well was photographed and all colonies were counted.

[0103] Transfection experiments. For luciferase assays , 24 hours before the experiment, different cells (5,000 cells / well) were seeded into 96-well plates using the corresponding culture medium as described above. The next day, nanoparticles were formed by mixing siRNA and CPP (equal volumes, "siRNA on CPP") in 5% glucose water and then incubated at 37°C for 30 minutes. At the same time, the growth medium covering the cells was replaced with 70 μL of fresh pre-warmed serum-free DMEM. 30 μL of the nanoparticle solution was added directly to the cells and incubated at 37°C for 1.5 hours. After adding DMEM supplemented with 20% FBS (final FBS concentration = 10%), the cells were further incubated for 36 hours and finally lysed for luciferase detection. For transfection in the presence of serum, the cells were incubated with nanoparticles in DMEM + 10% FBS at 37°C for 1.5 hours, and then DMEM supplemented with 10% FBS was added to the cells, further incubated for 36 hours, and then final cell lysis was performed to detect luciferase.

[0104] For Western blot assay , 75,000 U87 cells / mL / well were seeded into 24-well plates 24 hours before the experiment using the corresponding culture medium as described above. For standard incubation, the cells were incubated with 175 μL of fresh pre-warmed serum-free DMEM + 75 μL of the nanoparticle solution. After incubation for 1.5 hours, 250 μL of LDMEM + 20% FBS was added to each well without removing the transfection reagent, and the cells were incubated for another 24 hours. The experimental procedure was designed to test peptide: siRNA nanoparticles at a peptide: siRNA molar ratio of R = 20 and siRNA concentrations of 5, 10 and 20 nM in a final volume of 500 μL. After adding DMEM + 20% FBS (final 10% FBS), the cells were further incubated for 24 hours and finally lysed for CDK4 Western blot detection.

[0105] For microscopy experiments , 24 hours before imaging, 300,000 U87 cells were seeded into glass bottom dishes (FluoroDish, World Precision Instruments). Before the experiment, the cells were washed twice with D-PBS and covered with 1,600 μL of complete medium. Afterwards, 400 μL of NP (peptide: siRNA; R = 20, siRNA = 20 nM) prepared in 5% glucose in water was added directly onto the cells as described above.

[0106] Cytotoxicity measurements.Using the Cytotoxicity Detection Kit Plus (LDH, Roche Diagnostics), and 50 μL of the supernatant was evaluated for nanoparticle-induced cytotoxicity according to the manufacturer's instructions.

[0107] Luciferase reporter gene silencing assay . The siRNA delivery using different vectors was evaluated by measuring the remaining firefly luciferase (FLuc) activity in the cell lysate. Briefly, after 36 hours, the medium covering the cells was carefully removed and replaced with 50 μL of 0.5X passive lysis buffer (PLB; Promega). After shaking at 4°C for 30 minutes, the plate containing the cells was centrifuged (10 min, 1,800 rpm, 4°C), and finally 5 μL of each cell lysate supernatant was transferred to a white 96-well plate. For U87-FLuc-NLuc cells, as reported elsewhere (G. Aldrian et al., (2017) J. Control. Release Off. J. Control. Release Soc. 256, 79-91), the two luciferase activities were quantified using a half-diluted dual luciferase assay reagent (Promega) by a plate reader luminometer (POLARstar Omega, BMG Labtech). Results are expressed as percentage of relative light units (RLU) for each luciferase, which were normalized first to untreated cells (%FLuc and %NLuc) and then to %NLuc values ​​to obtain relative Luc activity (%FLuc / %NLuc).

[0108] For other cell lines with only FLuc expression, luciferase activity was quantified using a plate reader luminometer using a half-diluted luciferase assay reagent (Promega). Results are expressed as a percentage of relative light units (RLU) normalized to untreated cells (% FLuc).

[0109] Western blotting.The transfected cells were washed in PBS and lysed in RIPA buffer [50 mM Tris pH 8.0, 150 mM sodium chloride, 1% Triton X-100, 0.1% SDS (sodium dodecyl sulfate, Sigma-Aldrich), containing protease inhibitors (SigmaFAST, Sigma-Aldrich)]. The cells were incubated on ice for 5 minutes with 130 μL / 24-well lysis buffer. Afterwards, the cells were broken and transferred to a 1.5 ml tube. After 5 minutes on ice, the cell lysate was centrifuged (10 min, 13,400 rpm, 4°C), the supernatant was collected, and the protein concentration was determined using the Pierce BCA protein assay (ThermoFisher). The protein concentration was determined by 4-20% TGXTM Precast gel (Bio-Rad) was used to separate the cell extracts (0.25-0.38 μg / μL). After electrophoresis, the samples were transferred to Turbo TM Mini PVDF Transfer membrane (Bio-Rad). As antibodies (all from Cell Signaling), we used anti-cyclin B1 mouse mAb V152, anti-CDK4 rabbit mAb D9G3E, anti-vinculin rabbit mAb E1E9V, anti-mouse IgG HRP and anti-rabbit IgG HRP. Blots were visualized with Pierce ECL plus Western Blotting Substrate (ThermoFisher) on an Amersham Imager 600 (GE Healthcare Life Science). The signal intensity of the blots was quantified by Image J.

[0110] Confocal microscopy . For cell imaging by confocal microscopy , using an inverted LSM780 multiphoton microscope (Zeiss). After adding NPs, cells were incubated in a humidified incubator at 5% CO2 and 37°C for 1 hour. 10 minutes before the end of incubation, Hoechst 33342 dye was added to the cells for nucleus labeling. Then, the cells were washed twice with D-PBS and covered with FluoroBrite DMEM medium (Life Technologies). Confocal images were projected and processed with ImageJ software.

[0111] For the rotating disk experiment, an inverted microscope (Nikon Ti Eclipse) coupled to a turntable (ANDOR) system was used to study the internalization kinetics of NPs in living cells. After adding NPs, cells were maintained at 37°C by a cage incubator (Okolab), and images were directly recorded every 5 seconds for 1200 seconds with an EM-CCD camera (iXon Ultra), and projected with Andor IQ3 software. Control experiments were performed to ensure that no emission bleedthrough was observed between different channels. All images were processed using ImageJ software.

[0112] In vivo mouse experiments: Immunodeficient NOG (NOD / SCID / IL-2Rγnull) mice aged 6 to 10 weeks were housed at the University of Bordeaux animal facility. Mice maintained under specific pathogen-free conditions were maintained under standard conditions with a 12-hour light-dark cycle and ad libitum access to water and food. Anesthesia was performed using air containing 2% isoflurane (Belamont, Nicholas Piramal Limited, London, UK). The area of ​​the mouse to be imaged was previously shaved with a hair clipper and depilatory cream.

[0113] The mice were injected with U87-FRT-CMV-Fluc-CMV-Nluc cells (2x10 6 Subcutaneous tumors were generated by PCR with 4% paraformaldehyde (400 μL) of PBS (100 μL of PBS). Subcutaneous tumors were imaged 4 weeks after implantation.

[0114] mRNA extraction and quantitative RT-PCR: Total mRNA was isolated from U87 cells using Trizol (Thermo Fisher Scientific). 1 mg of total RNA was used for cDNA synthesis using NucleoSpin RNA (Macherey-Nagel). FastSYBR Green Master Mix (Invitrogen) was used to perform quantitative PCR using MySYq Quantitative (Bio-Rad). The primers used for Fluc amplification were Fluc-Fw: TCCATTCCATCACGGTTTTGG (SEQ ID N°9), Fluc-Rv: GCTATGTCTCCAGAATGTAGC (SEQ ID N°10), GAPDH-Fw: GCCAAGGTCATCCATGACAAC (SEQ ID N°11), GAPDH-Rv: GAGGAGTGGGTGTCGCTGTTG (SEQ ID N°12).

[0115] Reactions were performed in triplicate in three independent experiments. Data were normalized to the geometric mean of the housekeeping gene GAPDH to control for variability in expression levels and were expressed using 2 DDCt Method for analysis.

[0116] result

[0117] 1. Characterization of peptides:

[0118] In this experiment, several amphiphilic peptides have been studied and compared for their ability to form peptide-based nanoparticles (PBNs) to deliver therapeutic molecules (Table 1). Peptides CPP1 to CPP4 belong to the peptides of the present invention and consist of 3 amino acids: leucine, arginine and tryptophan residues. The peptides are 15 to 16 amino acids long, with an amide group (-CONH2) at the C-terminal portion and an amine (-NH2) at the N-terminal portion. All peptides of the present patent application have a net positive charge of +5 alone (+4 if the entity is coupled to the N-terminal portion).

[0119] Table 1: Sequences of cell penetrating peptides

[0120] ID sequence CPP AA Charge Nb CPP1 LLWRLWRLLWRLWRLL (SEQ ID N° 1) 16 5 4 CPP1-1 LWRLWRLLWRLWRL (SEQ ID N°13) 14 5 4 CPP2 LLRLLRWWWRLLRLL (SEQ ID N° 2) 15 5 3 CPP2-1 LRLRWWWRLRL (SEQ ID N°14) 11 5 3 CPP2-2 LLRLRWWWRLRLL (SEQ ID N°15) 13 5 3 CPP2-3 LRLLRWWWRLLRL (SEQ ID N°16) 13 5 3 CPP3 LLRLLRWWRLLRLL (SEQ ID N°3) 14 5 2 CPP4 LLRLLRWWWWRLLRLL (SEQ ID N°4) 16 5 4 C6M1 RLWRLLWRLWRRLWRLLR(SEQ ID N°17) 18 8 4 C6M1-L RLWRLWRLWRRLWRLLR(SEQ ID N°18) 17 8 4 P-CPP1 <![CDATA[PEG 2000 -LLWRLRRLWRRL]]> 16 4 4 P-CPP2 <![CDATA[PEG 2000 -LLRLLRWWWRLLRLL]]> 15 4 3 R-CPP2 RGD-Ahx-LLRLLRWWWRLLRLL 15 4 3 CPP1-4R RLLWRLW-----LWRLLR(SEQ ID N°19) 13 5 3 CPP1-6R RLLWRLWRLLWRLWRLLR(SEQ ID N°20) 18 7 4 CPP2-4R RLLRLL-WWW-LLRLLR(SEQ ID N°21) 15 5 3 CPP2-6R RLLRLLRWWWRLLRLLR(SEQ ID N°22) 17 7 3

[0121] footnote: CPP AA = amino acid number of the CPP sequence.

[0122] To examine the structural properties of the CPPs, a computer prediction of the 3D structure of each peptide was first performed. The sequences of CPP1 to CPP4 in a hydrophilic environment were submitted to the PepStrMOD server. After calculation, the peptide models generated by PepstrMOD revealed that all peptides adopted an α-helical structure ( Figure 1 ). CPP1 and CPP2 appear to exhibit more pronounced helicity than the other models.

[0123] The predicted structures were then compared with experimental studies. Circular dichroism spectra of the peptides were recorded free in solution, then in the presence of siRNA and then after the addition of liposomes. As shown in Table 2, all peptides (CPP1, CPP2, CPP3, and CPP4) adopt an alpha helical structure in the presence of siRNA molecules, even in the presence of neutral or negatively charged lipids ("large unilamellar vesicles" (LUV)).

[0124] Table 2: Conformational analysis of amphiphilic peptides by circular dichroism.

[0125]

[0126] Footnote: Random coil (rc) conformation has a positive band at 212nm and a negative band around 195nm. The helical conformation is characterized by two minima at 207nm and 222nm and a maximum around 191nm. Turn-like structures were observed with two minima at 200nm and 228nm. The CPP:siRNA molar ratio was R 20, the CPP:lipid molar ratio was r10, and the CPP concentration was 40μM.

[0127] 2. Colloidal Characterization of Amphiphilic Peptides

[0128] The conformational changes detected by CD suggested that almost all CPPs interacted with siRNA. To evaluate the complexation of siRNA, the formation of CPP:siRNA complexes was studied by agarose shift assay ( Figure 2 ). Alone siRNA is able to migrate in agarose gels (= 100% signal), but when complexed with CPPs, the peptides prevent the migration of the oligonucleotide in a molar ratio dependent manner. CPP1, CPP2, CPP3 and CPP4 are apparently able to complex siRNA in a similar manner, with optimal complexation at peptide:siRNA molar ratios of R=20 and R=40.

[0129] The colloidal characteristics of CPP: siRNA complexes (5% glucose, R = 20) were characterized based on nanoparticle size and uniformity obtained by dynamic light scattering (DLS). Intensity measurements (%) revealed that CPP1, CPP2, CPP3, and CPP4 formed PBNs with diameters between 80 nm and 200 nm and a polydispersity index (PdI) of approximately 0.3 (Table 3). The number (%)-based nanoparticle size distribution suggested that in addition to the nanoparticles found by the intensity-based size distribution, there were also smaller nanoparticles. For the four CPP: siRNAs, the diameters of these smaller particles were between 20 nm and 50 nm (Table 3). More importantly, even after storage at 4°C for 72 hours, the size values ​​of these two measurements did not change significantly (data not shown).

[0130] PBNs composed of CPP1:siRNA or CPP2:siRNA have both a positively charged surface (zeta potential measurement, Table 3) and a spherical shape as measured by transmission electron microscopy ( Figure 2 B).

[0131] Table 3: CPP characterization by DLS measurements.

[0132]

[0133] footnote:All CPP:siRNA complexes were formed at 500 nM siRNA concentration in 5% glucose in water at R=20 for average size acquisition and in 5% glucose in water with 5 mM NaCl for ZP evaluation. n≥2 independent preparations (3 measurements / run). nd: not determined. *ZP was measured in 5% glucose with 1 mM NaCl.

[0134] 3. The efficacy of siRNA-loaded CPP nanoparticles depends on the formulation

[0135] The efficacy of siRNA loaded CPP nanoparticles was evaluated according to the concentration applied during formulation.

[0136] Compare two different formulations:

[0137] 1) Dilution conditions: The complexes were prepared at higher concentrations (e.g., CPP [10 μM]: siRNA [0.5 μM]) and then diluted to final siRNA concentrations of 5 nM, 10 nM, and 20 nM for cell culture assays.

[0138] 2) Volume: Volume conditions: CPP and siRNA solutions were prepared separately and then mixed together to obtain final siRNA concentrations of 5 nM, 10 nM, and 20 nM for cell culture assays.

[0139] Taking formulation with CPP2 as an example, the knockdown efficiency of nanoparticles can be increased depending on the formulation procedure applied ( Fig.14 ). The diluted conditions appear to induce a higher knockdown efficiency (2-fold increase). This is particularly interesting for transfecting cells that are known to be "difficult" to transfect.

[0140] 4. Amphiphilic peptides can be used to prepare plasmids:

[0141] CPP1 and CPP2 peptides form complexes when they bind to oligonucleotides such as plasmids ( Figure 3 ). The formation of the complex was visualized using an agarose gel (0.5%) as described above for the complexation of CPP with siRNA. The plasmid was complexed by the CPP at a charge ratio (CR) corresponding to charge neutrality (CR=1) between the CPP (positive charge) and the plasmid (negative charge). The bulky CPP:plasmid complex was then no longer able to migrate into the agarose gel.

[0142] The intensity of the individual plasmid bands was normalized to 100%. By gradually increasing the CPP:plasmid charge ratio, complexation of the pGL3 plasmid (6.56 kbp) was obtained, proportionally reducing its migration into the agarose gel (0.5%).

[0143] To analyze the transfection potential of plasmid-loaded CPP nanoparticles, MCF7 (human breast cancer) and MEF (mouse embryonic fibroblast) cells were transfected with a plasmid encoding firefly luciferase (pGL3). After incubation with CPP2:pGL3 (CR=1) for 24 h, the cells were lysed and the expression of firefly luciferase was quantified by adding the substrate of firefly luciferase (Promega kit). Figure 3 As shown in B and 3C, a dose-dependent increase in firefly luciferase activity was observed compared to untreated cells, which correlated with increased protein expression.

[0144] In conclusion, the PBN can also be used to transfect plasmids, as shown previously with siRNA.

[0145] 5. Characterization of Cellular Activity of CPP:siRNA Nanoparticles in Luciferase Screening Assay

[0146] The cellular activity of CPP-based nanoparticles was evaluated in a luciferase screening assay as previously described (L. N. Patel et al., (2007) Pharm. Res. 24, 1977-1992; A. Elmquist et al., (2001) Exp. Cell Res. 269, 237-244.). The knockdown efficiency of different CPP: siRNA nanoparticles was performed on a U87 cell line stably transfected to constitutively express a FLuc / NLuc reporter gene (U87-FRT-CMV / Fluc-CMV / iRFP-IRES-NLuc).

[0147] First, we investigated the optimal molar ratio between peptide and siRNA (constant concentration 20 nM) required for efficient luciferase knockdown ( Figure 4 A). For CPP1, CPP2, CPP3 and CPP4 we observed significant luciferase knockdown of greater than 70% at R = 20, whereas this was slightly increased at R = 40. In parallel, no relative cytotoxicity (LDH measurement) was observed for all nanoparticle treatments.

[0148] Very promising results of firefly luciferase knockdown were observed after 36 hours of total transfection and also after 24 hours, which is a significant gain for the experimenter. At molar ratios R 20 and R 40 of CPP2:siRNA and CPP4:siRNA, the relative reduction of the luciferase signal was the same in all conditions (~60-80%), regardless of the transfection time applied ( Figure 4 B).

[0149] The optimal siRNA concentration was then elucidated by using the optimal peptide:siRNA molar ratio of R = 20 ( Figure 4C). The three PBNs (CPP1, CPP2 and CPP4) showed a very good dose-dependency relationship, showing a significant knock-down efficiency with an IC50 value of about 7.5 nM. Here again, no cytotoxicity was detected under all conditions used.

[0150] Finally, we can realize that the proposed nanoparticles are RNAiMAX (currently commercially available from ThermoFisher for siRNA transfection) induced comparable reductions in luciferase knockdown at the same siRNA concentrations used. Significant cytotoxicity equivalent to 21% was observed with RNAiMAX vectors ( Figure 4 C).

[0151] For repeated or long-term use of the nanoparticles, it is preferred to use isoform D of the CPP to reduce its degradation by extracellular or intracellular proteases. In this case, the efficiency of the CPP2:siRNA nanoparticles was evaluated using peptides in the L or D configuration.

[0152] The study of the colloidal properties revealed that the isoform D peptide CPP2 (CPP2[D]) formed nanoparticles of the same size as CPP2[L] (I% = 70 ± 11 nm, Nb% = 31 ± 1 nm, PdI = 0.302 ± 0.024, see also Table 3 for CPP2[L]), as confirmed by DLS.

[0153] In parallel, a dose-dependent (1 nM to 20 nM siRNA) decrease in firefly luciferase expression was observed at a constant ratio R 20, thus independent of the isomerization of the peptide (CPP2[D] and CPP2[L]) ( Figure 5 ).

[0154] To simulate in vivo applications, the nanoparticles were incubated in the presence of serum to mimic potential interactions with serum proteins when administered by intravenous injection. The presence of serum (10%) had no significant detrimental effect on the activity of the nanoparticles in silencing firefly luciferase at 15 nM and 20 nM siRNA against CPP1 and 10 nM to 20 nM siRNA against CPP2 ( Figure 6 ). A decrease of about 70% in luciferase activity was observed in the presence of 10% serum, which is equivalent to the absence of serum.

[0155] Finally, we demonstrated that the siRNA transfection carried out by CPP is reproducible between laboratories and has nothing to do with the detection method used. In this comparison, U87 cells were incubated with CPP2:siRNA nanoparticles at three concentrations of siRNA (5nM, 10nM and 20nM). After incubation, the cells were lysed and the activity of firefly luciferase and NanoLuc was quantified in the cell lysate transferred to 96-well plates (Dual Luciferase kit (Dual Luciferase kit), Promega, measured using PolarStar, BMG) or test tubes (luciferase assay reagent and Nano-Glo luciferase assay, Promega, measured using Lumat LB 9507, Berthold Technologies). In both cases, the values ​​showing that the dose-dependent reduction of firefly luciferase expression was identical ( Figure 7 ).

[0156] 6. Comparison of CPP:siRNA activity with other CPPs with similar sequences

[0157] Different sequence analogs of the two peptides, CPP1 and CPP2, were synthesized to show the importance of the amino acid position (CPP1 compared to C6M1) and the role of the leucine residues (CPP2 compared to CPP2-1 to CPP2-3, Table 1).

[0158] In order to show that our CPPs have a better efficiency in siRNA transfection than the C6M1 peptide published by Jafari et al. (2013), a direct comparison was performed. The C6M1-L sequence, which represents a C6M1 analog, contains a leucine deletion in the leucine duplex at the N-terminal position of the peptide sequence (Table 1 and Figure 8 A).

[0159] Human glioblastoma cells (U87) overexpressing firefly luciferase were incubated with nanoparticles encapsulated with siRNA (siFluc or siSCR as negative controls) formulated with four carrier peptides CPP1, C6M1, C6M1-L and CPP2. For all peptides, the same concentration (CPP = 200nM and siRNA = 10nM) was used, and these preparations were performed in parallel in the same manner. All solutions were then incubated in P96 plates containing 5.000 cells / well for 1.5 hours to avoid bias between incubations.

[0160] After luciferase activity measurement, we clearly showed that CPP1:siRNA and CPP2:siRNA could induce a 90% reduction in luciferase expression. In contrast, we observed luciferase knockdown equivalent to only 60% for C6M1:siRNA and 40% for C6M1-L:siRNA ( Figure 8 A).

[0161] In conclusion, the CPP1 peptide was 3-fold more active than C6M1 and 6-fold more active than C6M1-L in reducing luciferase expression (p=**** for both comparisons, one-way ANOVA with Tukey post hoc test). In addition, we could show that even the CPP2 peptide was more effective than C6M1 (2-fold) and C6M1-L (3.5-fold).

[0162] To understand the importance of the leucine "doublet" in the peptide sequence, we generated analogs by removing leucine residues at different positions (see Table 1). When only the middle "doublet" (CPP2-1) or the entire "doublet" (CPP2-2) of the CPP2 sequence was replaced with a simple leucine residue, we observed complete inactivation of the nanoparticles in the luciferase assay ( Figure 8 B).

[0163] In a second step, we wanted to analyze the importance of the "duplexes" at the N- and C-terminal positions of the CPP1 and CPP2 sequences (CPP1-1 and CPP2-3, respectively). This deletion also affected the activity of the nanoparticles (siRNA-FLuc) in cells (incellulo). Figure 8 B):

[0164] - Nanoparticles CPP2-3:siFLuc showed no activity in luciferase silencing compared to that observed with CPP2:siFluc PBN.

[0165] - The inhibitory activity of CPP1-1:siFLuc nanoparticles was reduced, especially at 10 nM and 20 nM siRNA concentrations, which corresponded to 3x and 5x-fold lower activity of this PBN compared to the same concentration of CPP1:siFLuc nanoparticles.

[0166] In the third step, we wanted to confirm the consensus sequence of the CPPs we developed and their respective behavior compared to C6M1 and C6M1-L. Therefore, peptide sequences were synthesized with additional arginine residues at the ends (N-terminus and C-terminus) of the peptide sequences (see CPP1-6R and CPP2-6R sequences in Table 1).

[0167] However, the addition of two arginines within the sequence will also increase the overall net charge of the peptide. To obtain the same net charge as the parent peptide, two additional peptides were designed with N- and C-terminal arginine residues but lacking two internal arginine residues (CPP1-4R and CPP2-4R, Table 1). In all cases, the addition of arginines at both ends of the peptide reduced the activity of the nanoparticle (siRNA-FLuc) in cells ( Figure 8 B):

[0168] - Nanoparticles CPP1-4R:siFLuc showed no activity in luciferase silencing compared to that observed for CPP1:siFluc PBN. Nanoparticles CPP1-6:siFLuc had reduced inhibitory activity, which corresponded to 4x-fold (5nM siRNA) and 3x-fold (10nM and 20nM siRNA) lower activity of this PBN compared to the same concentrations of CPP1:siFLuc nanoparticles.

[0169] - The inhibitory activity of the nanoparticles CPP2-4R:siFLuc and CPP2-6R was reduced at all siRNA concentrations, which corresponded to a 3x to 4x fold lower activity of this PBN compared to CPP2:siFLuc nanoparticles. In addition, CPP2-4R showed some variability in the luciferase activity measurements, which may be due to some cytotoxic effects of the nanoparticle incubation.

[0170] -DLS measurements explain the results obtained (Table 3): CPP1-4R:siRNA is more aggregated than the parental nanoparticles, CPP1-6R:siRNA particles are larger and more polydisperse than CPP1:siRNA, CPP2-4R:siRNA and CPP2-6R:siRNA appear to form smaller nanoparticles but appear more polydisperse compared to the nanoparticles obtained with CPP2:siRNA.

[0171] In conclusion, CPP1 and CPP2 possessed both the best amino acid combination that allowed stable nanoparticle formation and the highest knockdown efficiency.

[0172] 7. Example of transfection efficiency of CPP: siRNA nanoparticles:

[0173] Since they showed the best transfection efficiency, CPP1 and CPP2 were selected for additional cellular studies and development. To evaluate their potential as universal transfection agents, the two peptides were tested on different cell lines. Using 20 nM siRNA in U87 (human glioblastoma), KB (keratinocytes derived from Hela), HuH7 (human hepatocarcinoma) and Neuro2a (murine neuroblastoma), MCF7 (human breast), MDA-MB-231 (human breast adenocarcinoma) cells, using 50 nM siRNA in CMT93 (rectal cancer), MEF-RAS: Ras-modified mouse embryonic fibroblasts, A549: alveolar basal epithelial cells of human adenocarcinoma, HT29 (human colon cancer) and RM1 (murine prostate cancer) cells, and using 100 nM siRNA in GL261 (murine glioblastoma) cells, 50% to 80% FLuc gene silencing was detected, suggesting that some cell lines require higher siRNA doses to achieve comparable knockdown efficiency ( Fig. 9 A).

[0174] NPs based on CPP1 and CPP2 were also applied to target the endogenous protein cyclin-dependent kinase 4 (CDK4), which is known to be overexpressed in glioblastoma (DWParsons et al., (2008) An integrated genomic analysis of human glioblastoma multiforme, Science. 321, 1807–1812). Significant CDK4 knockdown was observed for both peptides, with 5nM, 10nM, and 20nM corresponding to 30%, 60%, and 80% inhibition of CDK4 expression, respectively. CPP1:siCDK4 appears to have a slightly higher effect on CDK4 knockdown than CPP2:siCDK4 ( Fig. 9 B).

[0175] and A direct comparison with RNAiMAX (a lipid transfection molecule sold by Thermo Fisher) clearly demonstrates the advantages of the PBN transfection system ( Fig. 9 C) Both transfection systems are effective in significantly knocking down CDK4, but RNAiMAX conditions showed a clear cytotoxic effect at low concentrations. Cytotoxicity can be observed in Western blots using an internal control (vinculin expression: dark grey bars) or total protein concentration (measured by BCA kit, red values).

[0176] At 50 nM siCDK4 concentration, CPP1 induced CDK4 knockdown greater than 80% without any cytotoxicity. When RNAiMAX agent was transfected with siRNA, the knockdown was the same but was accompanied by a significant decrease in the amount of total cellular protein and focal adhesion protein, indicating significant cytotoxicity of this transfection agent (red dashed line).

[0177] In contrast to the two RNAiMAX conditions that displayed extremely high toxicity profiles on cell survival and proliferation, cytotoxicity of CPP2 was also observed by clonogenic assay ( Fig. 9 D). All other CPP2 conditions had no effect on cell survival and proliferation compared to untreated cells. As expected, the control condition using siRNA against the cyclin D1 protein implemented in the cell cycle showed a 50% reduction in cell survival.

[0178] The effect of CPP2-based NPs on the endogenous protein CDK4 was also evaluated after three consecutive administrations of NPs over the next three days of culture. Fig. 9 E). Significant CDK4 knockdown was detected for all conditions, but a cumulative effect was clearly observed for three consecutive doses of 20 nM siRNA (dose 3) compared to a single administration (dose 1), suggesting a potential cumulative effect of CPP2-based NPs over time.

[0179] 8. Example of transfection efficiency of CPP:siRNA nanoparticles on cell suspension:

[0180] In order to evaluate the transfection potential of CPP nanoparticles loaded with siRNA for non-adherent cells (suspension), so-called reverse transfection was performed on U87 cells. Under "standard" transfection conditions, cells are plated in microtiter plates at the desired concentration and, after adhesion to the bottom of the wells (6 to 24 hours), the cells are transfected with nanoparticles. During "reverse" transfection, the nanoparticles are transferred to a microtiter plate and then trypsinized cells resuspended in medium with or without serum are added to the nanoparticles (see Fig.15 A and B).

[0181] In both cases, CPP1:siFLuc and CPP2:siFLuc showed dose-dependent silencing of the luciferase gene, which was specific, as CPP:siSCR nanoparticles did not show any knockdown efficiency. This silencing specificity was equally observed in medium without or with serum. However, the silencing efficiency of the reverse transfection required a slightly higher siRNA dose (50nM instead of 20nM) to obtain the same 80-90% knockdown as the "standard" transfection.

[0182] Next, the transfection potential of CPP2:siFLuc was evaluated on non-adherent cells such as U937 human macrophages stably transfected with firefly luciferase ( Fig.15 C). CPP2:siFLuc nanoparticles showed dose-dependent luciferase gene silencing, which was specific to the transfection as siFLuc alone did not show any knockdown efficiency. For siRNA concentrations of 10 nM, 20 nM and 50 nM, silencing efficiencies of 40%, 80% and 100% were measured, respectively.

[0183] 9. Co-transfection of CPP1:MBBO and CPP2:plasmids in the context of cystic fibrosis

[0184] Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs, but also the pancreas, liver, kidneys and intestines. It is caused by mutations in both gene copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Recently, it has been found that CFTR is post-transcriptionally regulated by micorRNAs such as miR-145 and miR-494 (Gillen AE et al., Biochem J. 2011; Megiorni F et al., Plos One, 2011; Ramachandran S et al., PNAS, 2012, Viart V et al., Eur Respir J. 2015). Several miRNAs including miR-145 are expressed in primary human airway epithelial cells, where the expression of CFTR is suppressed (Gillen AE et al., Biochem J, 2011) or dysregulated (Oglesby IK et al., J immunol, 2013; Ramachandran S et al., AJRCMB. 2013).

[0185] Dr. Taulan-Cardars' team designed a target site blocker (TSB, also known as miRNA binding-blocker oligonucleotide, MBBO) to prevent several miRNAs, including miR-101, miR-600, miR-145 and miR-384, from binding to the 3'-UTR of the CFTR gene (PCT / EP2014 / 069522). This MBBO can be encapsulated by CPP1 in a molar ratio-dependent manner and is fully complexed at R=5 ( Fig.16 A). Using this molar ratio, we obtained nanoparticles with an average size of 180 nm as determined by dynamic light scattering (DLS) ( Fig.16 B).

[0186] We then evaluated the effects of MMBO transfection on bronchial Beas-2b cells ( Fig.16C) The effect of the amount of CFTR transcript in the co-transfection experiment. In the co-transfection experiment, the plasmid encoding CFTR (pm-cDNA-CFTR-3'UTR, 11.8kbp) was transfected with different MBBOs (19-28pb). The CFTR transcript level was first normalized to the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and then to the control MBBO (MBP-Ctrl without 3'-UTR binding properties). Three different transfection agent combinations were analyzed:

[0187] -Lipofectamin TM RNAiMAX was used for both CFTR plasmid transfection and MBBO transfection

[0188] - For CFTR plasmid transfection, CPP1 for MBBO transfection

[0189] -CPP2 was used for CFTR plasmid transfection, and CPP1 was used for MBBO transfection.

[0190] like Fig.16 C shows the amount of CFTR transcripts in bronchial Beas-2b cells after CPP2: plasmid / CPP1: MBBO transfection and the use of The results of transfection with plasmid / CPP1:MBBO were 2 to 3 times higher than those with :plasmid / RNAiMAX:MBBO conditions were even 10 to 12 times higher. This increase in CFTR transcripts is associated with better transfection properties of plasmid and MBBO over transfection based on CPP1 and CPP2 peptides.

[0191] 10. Evaluation of the internalization kinetics of siRNA-loaded PBNs:

[0192] Nanoparticles based on CPP1 and CPP2 showed remarkable efficiency in gene silencing, suggesting optimal siRNA delivery. Therefore, we sought to evaluate its time-dependent cellular internalization. PBNs loaded with siRNA (20nM siFLuc) were applied to human U87 cells during different incubation times from 5 minutes to 90 minutes, and then the PBN solution was replaced with medium containing 10% FBS for 36 hours. The results revealed that after 5 minutes of incubation, CPP1 and CPP2 nanoparticles were already able to induce a 40% reduction in FLuc activity, suggesting a rapid and significant knockdown of the protein ( Fig.10 A). In addition, maximum and saturated FLuc silencing was observed after 60 min of incubation for both peptides without any cytotoxicity. Figure 4C, the maximum knockdown efficiency at 60 min was slightly lower, possibly due to: i) the lack of an additional 30 min incubation time; and ii) the PBN solution was replaced and not topped up with supplemented culture medium.

[0193] Similar time-dependent experiments performed with PBN loaded with siCDK4 revealed similar results after Western blot evaluation, confirming the rapid efficiency of transfection ( Fig.10 B). Here again, the first knockdown efficiency can be observed after 5 minutes of incubation, with the maximum silencing efficiency being reached at 60 minutes.

[0194] To obtain more information about the internalization of CPP-based nanoparticles, we performed confocal microscopy experiments. Representative images of siRNA cellular distribution reveal a punctate pattern ( Fig.10 C) is comparable to the pattern observed after 1 h of incubation for other PBNs (A. Vaissière et al., (2017) A retro-inverso cell-penetrating peptide for siRNA delivery, J. Nanobiotechnology. 15, 34.; G. Aldrian et al., (2017) PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo, J. Control. Release Off. J. Control. Release Soc. 256, 79–91.; A. et al. (2011) Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles, PloS One. 6, e25924.). We then performed a spinning disk experiment ( Fig.10D), The internalization kinetics of the two CPP-based nanoparticles were evaluated based on the cellular accumulation of Cy3b-labeled siRNA. As shown in the graphical representation, we observed that the siRNA delivered by these two PBNs reached maximum fluorescence (90% ± 5%) after incubation for ~15 minutes (900 seconds to 945 seconds). The IC50 values ​​(50%) of internalization were obtained after 240 seconds and 185 seconds of incubation of CPP1 and CPP2 nanoparticles, respectively. This internalization is very fast compared to previously analyzed PBNs such as RICK:siRNA or 20% PEG-RICK:siRNA, which reached internalization maximum after 120 minutes of incubation (A. Vaissière et al., (2017) A retro-inverso cell-penetrating peptide for siRNA delivery, J. Nanobiotechnology. 15, 34.; G. Aldrian et al., (2017) PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo, J. Control. Release Off. J. Control. Release Soc. 256, 79–91.). In summary, the observed rapid siRNA internalization kinetics of these two CPP-based nanoparticles can explain the knockdown efficacy observed even after 5 minutes of incubation ( Fig.10 A and 10B).

[0195] 11. In vivo evaluation of nanoparticles (mouse xenograft model):

[0196] To evaluate the efficiency of the nanoparticles in vivo, they were injected into subcutaneous tumors (murine U87-CMV-FLuc-CMV-iRFP-IRES-Nluc cells). 6 Cells / 100 μL) were injected subcutaneously into the right leg of B6 albino mice. After tumor growth, CPP2: siFluc nanoparticles (20 μL) were injected into the center of the tumor. Bioluminescence imaging (BLI) was performed using Lumina LT software (PerkinElmer Inc.) on Vivoptic (UMS 3767-Bordeaux University). Mice received an intraperitoneal injection of D-luciferin and images were taken 8 minutes after injection after administration of anesthetic solution (2% isoflurane).

[0197] Representative images of “dual” bioluminescence (Fluc and Nluc) and fluorescence (iRFP) showing visible reduction of firefly luciferase at 24 h ( Fig.11 A). This phenomenon was more pronounced in the average of a larger number of animals (n=11), revealing a 70% reduction in luciferase signal at 24 hours (*p<0.05) (CPP2:siFluc with 15 μg siFluc, R=20) ( Fig.11 B). More importantly, at 48 hours after injection of CPP2:siFluc nanoparticles, the mRNA-Fluc rate decreased by 80% (***p=0.0009) ( Fig.11 C).

[0198] 12. Delivery of siRNA "cocktails" via CPP nanoparticles:

[0199] The CPP-based peptide nanoparticles can also allow the delivery of a "cocktail" of several different siRNAs targeting different proteins, such as the following example of a mixture of two siRNAs (in equal ratios) targeting cyclin B1 and CDK4 proteins ( Fig.12 A) and a mixture of two siRNAs (in different ratios) ( Fig.12 B):

[0200] 13. Evaluation of highly modular nanoparticles (grafted PBN):

[0201] Targeting of nanoparticles has become a necessary prerequisite for reducing the internalization of therapeutic molecules in healthy tissues and preventing adverse side effects. For several years, targeting molecules such as peptides or sugars have been grafted onto nanoparticles, which recognize receptors overexpressed in certain tissues or cell types (F. Danhier et al., (2012) Mol Pharm. 9 (11): 2961-73.; 22.; D. M. Copolovici et al., (2014) ACS Nano. 8 (3): 1972-94.; D. Arosio et al., (2017) Recent Pat Anticancer Drug Discov. 12 (2): 148-168.).

[0202] In the context of cancer, a targeting sequence consisting of three amino acids (RGD) is the most studied one to increase the specificity of a single therapeutic molecule or vector (UK Marelli UK et al., (2013) Front Oncol. 3:222.) This peptide is known to specifically interact with the αvβ3 integrin receptor overexpressed on the surface of cancer cells.

[0203] To perform a proof of concept for modulated nanoparticles, a linear sequence of RGD (with an aminohexanoic acid linker, Ahx) was grafted to the N-terminal portion of the peptide CPP2.

[0204] Using a luciferase assay, extending the CPP2 peptide by four residues did not appear to affect nanoparticle formation ( Fig.13 A). Luciferase expression was reduced by ∼70%, comparable to that of naked PBN ( Figure 4 Regardless of the percentage of grafted peptide used (ratio between CPP2 alone and RGD-Ahx-CPP2), the luciferase silencing level remained constant ( Fig.13 B).

[0205] The main limitation of using peptide-based nanoparticles is their short life span in the blood. However, thanks to the excessive peptide chemistry, PBN can be modified by functional entities to improve its pharmacological properties (T.Lehto et al., (2016) Drug Deliv. Rev. 106 (Pt A), 172-182). In this regard, PEGylation is widely used to improve their in vivo stability to prevent them from being recognized by the mononuclear phagocytic system (MPS) in the liver and spleen and interacting with blood components. For example, Genexol-PM [methoxy-PEG-poly (D, L-lactide) paclitaxel] is the first polymer-based micellar nanoparticle that has shown real success in Phase II clinical trials in the United States.

[0206] In this case, proof of concept has been achieved and it has been shown that the peptide nanoparticles described in this patent can be grafted with PEG entities, even poly-grafted ( Fig.13 C). Addition of 20% PEG-CPP had no significant effect on the activity of the nanoparticles. Only the condition of 100% PEG-CPP completely inhibited it. These results correlate with the data obtained with PEG-RICK (G. Aldrian et al., (2017) J. Control. Release Off. J. Control. Release Soc. 256, 79-91).

[0207] Furthermore, when the added PEG-CPP did not exceed 20%, the tripartite mixture formulated by inserting the targeting RGD peptide sequence (CPP2: 20% RGD-Ahx-CPP2: 20% PEG-CPP2) showed the same potential to reduce luciferase activity as the bare nanoparticles (CPP2) ( Fig.13 D). Sequence Listing <110> AXLR <120> Non-naturally occurring peptides useful as cell penetrating peptides <130> B2793PC00 <160> twenty two <170> PatentIn version 3.5 <210> 1 <211> 16 <212> PRT <213> Artificial sequence <220> <223> CPP1 <400> 1 Leu Leu Trp Arg Leu Trp Arg Leu Leu Trp Arg Leu Trp Arg Leu Leu 1 5 10 15 <210> 2 <211> 15 <212> PRT <213> Artificial sequence <220> <223> CPP2 <400> 2 Leu Leu Arg Leu Leu Arg Trp Trp Trp Arg Leu Leu Arg Leu Leu 1 5 10 15 <210> 3 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CPP3 <400> 3 Leu Leu Arg Leu Leu Arg Trp Trp Arg Leu Leu Arg Leu Leu 1 5 10 <210> 4 <211> 16 <212> PRT <213> Artificial sequence <220> <223> CPP4 <400> 4 Leu Leu Arg Leu Leu Arg Trp Trp Trp Trp Arg Leu Leu Arg Leu Leu 1 5 10 15 <210> 5 <211> twenty one <212> DNA <213> siRNA <400> 5 cuuacgcuga guacuucgat t 21 <210> 6 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> siRNA <400> 6 caucaucccu gccucuacut t 21 <210> 7 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> siRNA <400> 7 cagaucucgg ugaacgaugt t 21 <210> 8 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> siRNA <400> 8 aaccacucaa cuuuuuccca att 23 <210> 9 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primers <400> 9 tccattccat cacggttttg g 21 <210> 10 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primers <400> 10 gctatgtctc cagaatgtag c 21 <210> 11 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primers <400> 11 gccaaggtca tccatgacaa c 21 <210> 12 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primers <400> 12 gaggagtggg tgtcgctgtt g 21 <210> 13 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CPP1-1 <400> 13 Leu Trp Arg Leu Trp Arg Leu Leu Trp Arg Leu Trp Arg Leu 1 5 10 <210> 14 <211> 11 <212> PRT <213> Artificial sequence <220> <223> CPP2-1 <400> 14 Leu Arg Leu Arg Trp Trp Trp Arg Leu Arg Leu 1 5 10 <210> 15 <211> 13 <212> PRT <213> artificial sequence <220> <223> CPP2-2 <400> 15 Leu Leu Arg Leu Arg Trp Trp Trp Arg Leu Arg Leu Leu 1 5 10 <210> 16 <211> 13 <212> PRT <213> artificial sequence <220> <223> CPP2-3 <400> 16 Leu Arg Leu Leu Arg Trp Trp Trp Arg Leu Leu Arg Leu 1 5 10 <210> 17 <211> 18 <212> PRT <213> artificial sequence <220> <223> C6M1 <400> 17 Arg Leu Trp Arg Leu Leu Trp Arg Leu Trp Arg Arg Leu Trp Arg Leu 1 5 10 15 Silver Lion <210> 18 <211> 17 <212> PRT <213> artificial sequence <220> <223> C6M1-L <400> 18 Arg Leu Trp Arg Leu Trp Arg Leu Trp Arg Arg Leu Trp Arg Leu Leu 1 5 10 15 Silver <210> 19 <211> 13 <212> PRT <213> artificial sequence <220> <223> CPP1-4R <400> 19 Arg Leu Leu Trp Arg Leu Trp Leu Trp Arg Leu Leu Arg 1 5 10 <210> 20 <211> 18 <212> PRT <213> artificial sequence <220> <223> CPP1-6R <400> 20 Arg Leu Leu Trp Arg Leu Trp Arg Leu Leu Trp Arg Leu Trp Arg Leu 1 5 10 15 Silver Lion <210> 21 <211> 15 <212> PRT <213> artificial sequence <220> <223> CPP2-4R <400> 21 Arg Leu Leu Arg Leu Leu Trp Trp Trp Leu Leu Arg Leu Leu Arg 1 5 10 15 <210> 22 <211> 17 <212> PRT <213> artificial sequence <220> <223> CPP2-6R <400> 22 Arg Leu Leu Arg Leu Leu Arg Trp Trp Trp Arg Leu Leu Arg Leu Leu 1 5 10 15 Arg

Claims

1. A non-naturally occurring cell penetrating peptide, wherein the peptide consists of an amino acid sequence selected from the group consisting of LLWRLWRLLWRLWRLL (SEQ ID N°1), LLRLLRWWWRLLRLL (SEQ ID N°2) and LLRLLRWWWWRLLRLL (SEQ ID N°4).

2. The peptide according to claim 1, wherein the peptide comprises L-amino acids and / or D-amino acids.

3. The peptide according to claim 1 or 2, wherein the peptide has a net positive charge of 5.

4. The peptide according to claim 1 or 2, wherein the peptide further comprises one or more entities selected from L-amino acids, D-amino acids, non-natural amino acids, cysteamide, thiol, amide, carboxyl, optionally substituted linear or branched C1-C6 alkyl, primary or secondary amine, osidic derivatives, lipids, phospholipids, fatty acids, cholesterol, polyethylene glycol, nuclear localization signals and / or targeting molecules covalently linked to the C-terminus of the amino acid sequence, and / or wherein the peptide further comprises one or more chemical entities selected from L-amino acids, D-amino acids, non-natural amino acids, amines, acetyl, optionally substituted linear or branched C1-C6 alkyl, primary or secondary amine, osidic derivatives, lipids, phospholipids, fatty acids, cholesterol, polyethylene glycol, nuclear localization signals and / or targeting molecules covalently linked to the N-terminus of the amino acid sequence.

5. Use of a peptide according to any one of claims 1 to 4 as a cell penetrating peptide (CPP), wherein the use is not for the purpose of treating or diagnosing a disease.

6. Use according to claim 5, wherein the cell penetrating peptide (CPP) is suitable for penetrating the plasma membrane of mammalian cells.

7. Use of a peptide according to any one of claims 1 to 4 as a transfection agent, wherein the use is not for the purpose of treating or diagnosing a disease.

8. A nanoparticle comprising the peptide according to any one of claims 1 to 4 and a cargo molecule.

9. The nanoparticle of claim 8, wherein the cargo molecule is selected from the group consisting of nucleic acids, peptides, proteins, lipids, small molecules, pharmaceutically active agents, and any mixtures thereof.

10. The nanoparticle of claim 9, wherein the cargo molecule is a nucleic acid selected from a DNA molecule, an RNA molecule, a PNA molecule, an siRNA molecule, a PMO molecule, an antisense molecule, an LNA molecule, an mcDNA molecule, an miRNA molecule, a CRISPR / Cas9 molecule, a plasmid, a ribozyme, an aptamer, a spiegelmer, and a decoy molecule.

11. The nanoparticle according to any one of claims 8 to 10, wherein the size of the nanoparticle is between 50 and 300 nm, and / or wherein the cargo molecule is covalently or non-covalently bound to the peptide.

12. The nanoparticle according to claim 11, wherein the size of the nanoparticle is between 100 and 200 nm.

13. A pharmaceutical composition comprising the nanoparticle according to any one of claims 8 to 12 and a pharmaceutically acceptable carrier.

14. A method for delivering a cargo molecule into a cell in vitro, the method comprising the step of contacting the cell with a nanoparticle according to any one of claims 8 to 12, the nanoparticle comprising the cargo molecule.

15. A method for delivering a cargo molecule to a tissue and / or organ ex vivo, the method comprising the step of contacting the tissue and / or organ with a nanoparticle according to any one of claims 8 to 12, the nanoparticle comprising the cargo molecule.